What Happened?
Brisbane, CA-based Tioma Therapeutics Appointed James Stutz as Chief Business Officer
About the Company
Tioma is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. Our functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses.
About the Person
James Stutz is Chief Business Officer at Tioma Therapeutics. Previously, James held various senior HR leadership roles in the industry.
Info Source
News
Short Profile